The global RNA Interference (RNAi) Drug Delivery market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淩NA Interference (RNAi) Drug Delivery Industry Forecast鈥� looks at past sales and reviews total world RNA Interference (RNAi) Drug Delivery sales in 2024, providing a comprehensive analysis by region and market sector of projected RNA Interference (RNAi) Drug Delivery sales for 2025 through 2031. With RNA Interference (RNAi) Drug Delivery sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA Interference (RNAi) Drug Delivery industry.
This Insight Report provides a comprehensive analysis of the global RNA Interference (RNAi) Drug Delivery landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on RNA Interference (RNAi) Drug Delivery portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global RNA Interference (RNAi) Drug Delivery market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA Interference (RNAi) Drug Delivery and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA Interference (RNAi) Drug Delivery.
This report presents a comprehensive overview, market shares, and growth opportunities of RNA Interference (RNAi) Drug Delivery market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Nanoparticle Drug Delivery Technology
Pulmonary Drug Delivery Technology
Nucleic Acid Drug Delivery Technology
Aptamer Drug Delivery Technology
Segmentation by Application:
Infectious Diseases
Cardiology
Oncology
Neurology
Ophthalmology
Metabolic Disorders
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Metabolic disorders
Alnylam Pharmaceuticals Inc
Merck & Co. Inc
Access Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Calondo Pharmaceuticals Inc
Marina Biotech Inc
RXi Pharmaceuticals Corp
Quark Pharmaceuticals Inc
Silence Therapeutics plc
Tacere Therapeutics Inc
PhaseRx Inc
Sirnaomics Inc
Traversa Therapeutics Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global RNA Interference (RNAi) Drug Delivery market?
What factors are driving RNA Interference (RNAi) Drug Delivery market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do RNA Interference (RNAi) Drug Delivery market opportunities vary by end market size?
How does RNA Interference (RNAi) Drug Delivery break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global RNA Interference (RNAi) Drug Delivery Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for RNA Interference (RNAi) Drug Delivery by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for RNA Interference (RNAi) Drug Delivery by Country/Region, 2020, 2024 & 2031
2.2 RNA Interference (RNAi) Drug Delivery Segment by Type
2.2.1 Nanoparticle Drug Delivery Technology
2.2.2 Pulmonary Drug Delivery Technology
2.2.3 Nucleic Acid Drug Delivery Technology
2.2.4 Aptamer Drug Delivery Technology
2.3 RNA Interference (RNAi) Drug Delivery Sales by Type
2.3.1 Global RNA Interference (RNAi) Drug Delivery Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global RNA Interference (RNAi) Drug Delivery Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global RNA Interference (RNAi) Drug Delivery Sale Price by Type (2020-2025)
2.4 RNA Interference (RNAi) Drug Delivery Segment by Application
2.4.1 Infectious Diseases
2.4.2 Cardiology
2.4.3 Oncology
2.4.4 Neurology
2.4.5 Ophthalmology
2.4.6 Metabolic Disorders
2.5 RNA Interference (RNAi) Drug Delivery Sales by Application
2.5.1 Global RNA Interference (RNAi) Drug Delivery Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global RNA Interference (RNAi) Drug Delivery Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global RNA Interference (RNAi) Drug Delivery Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global RNA Interference (RNAi) Drug Delivery Breakdown Data by Company
3.1.1 Global RNA Interference (RNAi) Drug Delivery Annual Sales by Company (2020-2025)
3.1.2 Global RNA Interference (RNAi) Drug Delivery Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global RNA Interference (RNAi) Drug Delivery Annual Revenue by Company (2020-2025)
3.2.1 Global RNA Interference (RNAi) Drug Delivery Revenue by Company (2020-2025)
3.2.2 Global RNA Interference (RNAi) Drug Delivery Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global RNA Interference (RNAi) Drug Delivery Sale Price by Company
3.4 Key Manufacturers RNA Interference (RNAi) Drug Delivery Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers RNA Interference (RNAi) Drug Delivery Product Location Distribution
3.4.2 Players RNA Interference (RNAi) Drug Delivery Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for RNA Interference (RNAi) Drug Delivery by Geographic Region
4.1 World Historic RNA Interference (RNAi) Drug Delivery 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global RNA Interference (RNAi) Drug Delivery Annual Sales by Geographic Region (2020-2025)
4.1.2 Global RNA Interference (RNAi) Drug Delivery Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic RNA Interference (RNAi) Drug Delivery 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global RNA Interference (RNAi) Drug Delivery Annual Sales by Country/Region (2020-2025)
4.2.2 Global RNA Interference (RNAi) Drug Delivery Annual Revenue by Country/Region (2020-2025)
4.3 Americas RNA Interference (RNAi) Drug Delivery Sales Growth
4.4 APAC RNA Interference (RNAi) Drug Delivery Sales Growth
4.5 Europe RNA Interference (RNAi) Drug Delivery Sales Growth
4.6 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales Growth
5 Americas
5.1 Americas RNA Interference (RNAi) Drug Delivery Sales by Country
5.1.1 Americas RNA Interference (RNAi) Drug Delivery Sales by Country (2020-2025)
5.1.2 Americas RNA Interference (RNAi) Drug Delivery Revenue by Country (2020-2025)
5.2 Americas RNA Interference (RNAi) Drug Delivery Sales by Type (2020-2025)
5.3 Americas RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA Interference (RNAi) Drug Delivery Sales by Region
6.1.1 APAC RNA Interference (RNAi) Drug Delivery Sales by Region (2020-2025)
6.1.2 APAC RNA Interference (RNAi) Drug Delivery Revenue by Region (2020-2025)
6.2 APAC RNA Interference (RNAi) Drug Delivery Sales by Type (2020-2025)
6.3 APAC RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe RNA Interference (RNAi) Drug Delivery by Country
7.1.1 Europe RNA Interference (RNAi) Drug Delivery Sales by Country (2020-2025)
7.1.2 Europe RNA Interference (RNAi) Drug Delivery Revenue by Country (2020-2025)
7.2 Europe RNA Interference (RNAi) Drug Delivery Sales by Type (2020-2025)
7.3 Europe RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa RNA Interference (RNAi) Drug Delivery by Country
8.1.1 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Country (2020-2025)
8.1.2 Middle East & Africa RNA Interference (RNAi) Drug Delivery Revenue by Country (2020-2025)
8.2 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Type (2020-2025)
8.3 Middle East & Africa RNA Interference (RNAi) Drug Delivery Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of RNA Interference (RNAi) Drug Delivery
10.3 Manufacturing Process Analysis of RNA Interference (RNAi) Drug Delivery
10.4 Industry Chain Structure of RNA Interference (RNAi) Drug Delivery
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 RNA Interference (RNAi) Drug Delivery Distributors
11.3 RNA Interference (RNAi) Drug Delivery Customer
12 World Forecast Review for RNA Interference (RNAi) Drug Delivery by Geographic Region
12.1 Global RNA Interference (RNAi) Drug Delivery 麻豆原创 Size Forecast by Region
12.1.1 Global RNA Interference (RNAi) Drug Delivery Forecast by Region (2026-2031)
12.1.2 Global RNA Interference (RNAi) Drug Delivery Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global RNA Interference (RNAi) Drug Delivery Forecast by Type (2026-2031)
12.7 Global RNA Interference (RNAi) Drug Delivery Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Metabolic disorders
13.1.1 Metabolic disorders Company Information
13.1.2 Metabolic disorders RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.1.3 Metabolic disorders RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Metabolic disorders Main Business Overview
13.1.5 Metabolic disorders Latest Developments
13.2 Alnylam Pharmaceuticals Inc
13.2.1 Alnylam Pharmaceuticals Inc Company Information
13.2.2 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.2.3 Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Alnylam Pharmaceuticals Inc Main Business Overview
13.2.5 Alnylam Pharmaceuticals Inc Latest Developments
13.3 Merck & Co. Inc
13.3.1 Merck & Co. Inc Company Information
13.3.2 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.3.3 Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Merck & Co. Inc Main Business Overview
13.3.5 Merck & Co. Inc Latest Developments
13.4 Access Pharmaceuticals Inc
13.4.1 Access Pharmaceuticals Inc Company Information
13.4.2 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.4.3 Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Access Pharmaceuticals Inc Main Business Overview
13.4.5 Access Pharmaceuticals Inc Latest Developments
13.5 Dicerna Pharmaceuticals Inc
13.5.1 Dicerna Pharmaceuticals Inc Company Information
13.5.2 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.5.3 Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Dicerna Pharmaceuticals Inc Main Business Overview
13.5.5 Dicerna Pharmaceuticals Inc Latest Developments
13.6 Calondo Pharmaceuticals Inc
13.6.1 Calondo Pharmaceuticals Inc Company Information
13.6.2 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.6.3 Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Calondo Pharmaceuticals Inc Main Business Overview
13.6.5 Calondo Pharmaceuticals Inc Latest Developments
13.7 Marina Biotech Inc
13.7.1 Marina Biotech Inc Company Information
13.7.2 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.7.3 Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Marina Biotech Inc Main Business Overview
13.7.5 Marina Biotech Inc Latest Developments
13.8 RXi Pharmaceuticals Corp
13.8.1 RXi Pharmaceuticals Corp Company Information
13.8.2 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.8.3 RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 RXi Pharmaceuticals Corp Main Business Overview
13.8.5 RXi Pharmaceuticals Corp Latest Developments
13.9 Quark Pharmaceuticals Inc
13.9.1 Quark Pharmaceuticals Inc Company Information
13.9.2 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.9.3 Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Quark Pharmaceuticals Inc Main Business Overview
13.9.5 Quark Pharmaceuticals Inc Latest Developments
13.10 Silence Therapeutics plc
13.10.1 Silence Therapeutics plc Company Information
13.10.2 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.10.3 Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Silence Therapeutics plc Main Business Overview
13.10.5 Silence Therapeutics plc Latest Developments
13.11 Tacere Therapeutics Inc
13.11.1 Tacere Therapeutics Inc Company Information
13.11.2 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.11.3 Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Tacere Therapeutics Inc Main Business Overview
13.11.5 Tacere Therapeutics Inc Latest Developments
13.12 PhaseRx Inc
13.12.1 PhaseRx Inc Company Information
13.12.2 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.12.3 PhaseRx Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 PhaseRx Inc Main Business Overview
13.12.5 PhaseRx Inc Latest Developments
13.13 Sirnaomics Inc
13.13.1 Sirnaomics Inc Company Information
13.13.2 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.13.3 Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Sirnaomics Inc Main Business Overview
13.13.5 Sirnaomics Inc Latest Developments
13.14 Traversa Therapeutics Inc
13.14.1 Traversa Therapeutics Inc Company Information
13.14.2 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Product Portfolios and Specifications
13.14.3 Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Traversa Therapeutics Inc Main Business Overview
13.14.5 Traversa Therapeutics Inc Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
